

Supplementary webappendix

This webappendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. *Lancet Oncol* 2010; published online Dec 8.
DOI:10.1016/S1470-2045(10)70266-7.

	Randomised to radiotherapy and tamoxifen (n=242)	Randomised to no adjuvant therapy (n=226)	Hazard ratio (95% CI)	p value
Ipsilateral				
Invasive	9 (3·7%)	27 (10·1%)	0·30 (0·14–0·65)	0·002
DCIS	8 (2·9%)	27 (11·1%)	0·24 (0·10–0·56)	0·001
Unknown	0	2	..	..
All	17 (6·4%)	56 (22·7%)	0·25 (0·14–0·44)	<0·0001
Contralateral				
Invasive	5 (2·1%)	7 (2·8%)	0·69 (0·22–2·17)	0·5
DCIS	2 (0·05%)	6 (2·2%)	0·32 (0·06–1·57)	0·2
Unknown	1	0	..	..
All	8 (2·9%)	13 (4·0%)	0·59 (0·24–1·41)	0·2
All invasive	14 (5·8%)	32 (12·4%)	0·40 (0·21–0·75)	0·004
All DCIS	10 (3·3%)	33 (13·4%)	0·25 (0·12–0·52)	<0·0001
Unknown*	1	2	..	..
All recurrences	25 (9·5%)	67 (27·0%)	0·31 (0·19–0·49)	<0·0001

*Laterality or invasive unknown

Webtable 1: New breast events and 10-year estimates of percentages with an event in patients randomised to combined treatment or not

	Randomised to radiotherapy and tamoxifen (n=242)	Randomised to radiotherapy (n=220)	Hazard ratio (95% CI)	p value
Ipsilateral				
Invasive	9 (3.7%)	8 (2.7%)	1.37 (0.49–3.84)	0.6
DCIS	8 (2.9%)	11 (5.0%)	0.57 (0.22–1.48)	0.2
Unknown	0	0	..	..
All	17 (6.4%)	19 (7.8%)	0.85 (0.43–1.68)	0.6
Contralateral				
Invasive	5 (2.1%)	5 (2.3%)	0.91 (0.26–3.14)	0.9
DCIS	2 (0.4%)	2 (0.9%)	0.89 (0.13–6.35)	0.9
Unknown	1	2	..	..
All	8 (2.9%)	9 (4.1%)	0.80 (0.31–2.08)	0.7
All invasive	14 (5.8%)	14 (5.5%)	1.06 (0.49–2.28)	0.9
All DCIS	10 (3.3%)	14 (5.9%)	0.58 (0.25–1.33)	0.2
Unknown*	1	2	..	..
All recurrences	25 (9.5%)	30 (12.4%)	0.77 (0.44–1.32)	0.3

*Laterality or invasive unknown

Webtable 2: New breast events and 10-year estimates of percentages with an event in patients randomised to combined treatment or to radiotherapy alone

	Randomised to radiotherapy and tamoxifen (n=242)	Randomised to tamoxifen (n=224)	Hazard ratio (95% CI)	p value
Ipsilateral				
Invasive	9 (3·7%)	19 (8·5%)	0·43 (0·19–0·95)	0·04
DCIS	8 (2·9%)	19 (8·5%)	0·33 (0·14–0·79)	0·01
Unknown	0	2	..	..
All	17 (6·6%)	40 (17·4%)	0·35 (0·20–0·62)	<0·0001
Contralateral				
Invasive	5 (2·1%)	4 (1·8%)	1·16 (0·31–4·32)	0·8
DCIS	2 [#]	1 [#]	1·85 (0·17–20·46)	0·6
Unknown	1	0	..	..
All	8 (2·9%)	5 (1·8%)	1·49 (0·49–4·55)	0·5
All invasive	14 (5·8%)	23 (10·0%)	0·55 (0·28–1·07)	0·08
All DCIS	10 (3·3%)	21 (8·9%)	0·38 (0·18–0·84)	0·02
Unknown*	1	3	..	..
All recurrences	25 (9·5%)	47 (19·7%)	0·45 (0·28–0·74)	0·002

*Laterality or invasive unknown.

Webtable 3: New breast events and 10-year estimates of percentages with an event in patients randomised to combined treatment or to tamoxifen alone